Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Neuroblastoma × Ipilimumab × Clear all

Phase

Status

Completed 4 Withdrawn 1 Terminated 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 39 Carcinoma, Non-Small-Cell Lung 8 Neoplasms 6 Neoplasm Metastasis 6 Carcinoma, Renal Cell 5 Skin Neoplasms 4 Prostatic Neoplasms 4 Carcinoma, Hepatocellular 4 Small Cell Lung Carcinoma 3 Pancreatic Neoplasms 3 Ovarian Neoplasms 3 Multiple Myeloma 3 Lung Neoplasms 3 Glioblastoma 3 Breast Neoplasms 3 Advanced Cancer 3 Uveal Melanoma 2 Triple Negative Breast Neoplasms 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Myeloproliferative Disorders 2 Lymphoma, Non-Hodgkin 2 Lymphoma 2 Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 2 Leukemia, Myeloid, Acute 2 Leukemia, Lymphocytic, Chronic, B-Cell 2 Diabetes Mellitus, Insulin-Dependent, 12 2 Brain Neoplasms 2 Waldenstrom Macroglobulinemia 1 Very High Risk Prostate Carcinoma 1 Urinary Bladder Neoplasms 1

Interventions

Cyclophosphamide 6 Isotretinoin 5 thymoglobulin 4 fludarabine phosphate 4 fludarabine 4 Topotecan 4 Temozolomide 4 Melphalan 4 Irinotecan 4 Etoposide 4 ribociclib 3 aldesleukin 3 Thiotepa 3 Granulocyte Colony-Stimulating Factor 3 Filgrastim 3 Busulfan 3 Bone Marrow Transplantation 3 Antilymphocyte Serum 3 temsirolimus 2 Vincristine 2 Tretinoin 2 TPI-287 2 Stem Cell Transplantation 2 Radiotherapy 2 Peripheral Blood Stem Cell Transplantation 2 Nivolumab 2 Interleukin-2 2 Ifosfamide 2 Granulocyte-Macrophage Colony-Stimulating Factor 2 Flow Cytometry 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04239040 2025-03-19

GVAX Plus Checkpoint Blockade in Neuroblastoma

Dana-Farber Cancer Institute

Phase 1 Terminated

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡